122 related articles for article (PubMed ID: 28159504)
1. Detecting naloxone prejudices in the pharmacy setting.
Green TC; Potter N; Bratberg J;
J Am Pharm Assoc (2003); 2017; 57(2S):S10-S11. PubMed ID: 28159504
[No Abstract] [Full Text] [Related]
2. Opioids, naloxone, and beyond: The intersection of medication safety, public health, and pharmacy.
Bratberg JP
J Am Pharm Assoc (2003); 2017; 57(2S):S5-S7. PubMed ID: 28292503
[No Abstract] [Full Text] [Related]
3. Pharmacist-led health-system approaches to reduce opioid overdose and death.
Saldaña SN; Weaver N; Stanford B
J Am Pharm Assoc (2003); 2017; 57(2S):S8-S9. PubMed ID: 27865761
[No Abstract] [Full Text] [Related]
4. Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.
Freeman PR; Goodin A; Troske S; Strahl A; Fallin A; Green TC
J Am Pharm Assoc (2003); 2017; 57(2S):S28-S33. PubMed ID: 28139459
[TBL] [Abstract][Full Text] [Related]
5. Assessing the impact of clinical pharmacists on naloxone coprescribing in the primary care setting.
Watson A; Guay K; Ribis D
Am J Health Syst Pharm; 2020 Mar; 77(7):568-573. PubMed ID: 32207821
[TBL] [Abstract][Full Text] [Related]
6. Public attitudes and beliefs about Virginia community pharmacists dispensing and administering naloxone.
Haggerty LC; Gatewood SS; Goode JKR
J Am Pharm Assoc (2003); 2018; 58(4S):S73-S77.e1. PubMed ID: 30006189
[TBL] [Abstract][Full Text] [Related]
7. Development and delivery of a pharmacist training program to increase naloxone access in Kentucky.
Palmer E; Hart S; Freeman PR
J Am Pharm Assoc (2003); 2017; 57(2S):S118-S122. PubMed ID: 28161300
[TBL] [Abstract][Full Text] [Related]
8. Pharmacy-based statewide naloxone distribution: A novel "top-down, bottom-up" approach.
Morton KJ; Harrand B; Floyd CC; Schaefer C; Acosta J; Logan BC; Clark K
J Am Pharm Assoc (2003); 2017; 57(2S):S99-S106.e5. PubMed ID: 28292508
[TBL] [Abstract][Full Text] [Related]
9. The pharmacist's role in overdose: Using mapping technologies to analyze naloxone and pharmacy distribution.
Burrell A; Ethun L; Fawcett JA; Rickard-Aasen S; Williams K; Kearney SM; Pringle JL
J Am Pharm Assoc (2003); 2017; 57(2S):S73-S77.e1. PubMed ID: 28109629
[TBL] [Abstract][Full Text] [Related]
10. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
11. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
12. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
[TBL] [Abstract][Full Text] [Related]
13. State legal innovations to encourage naloxone dispensing.
Davis C; Carr D
J Am Pharm Assoc (2003); 2017; 57(2S):S180-S184. PubMed ID: 28073688
[TBL] [Abstract][Full Text] [Related]
14. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
Melaragni F; Levy C; Pedrazzi J; Andersen M
J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
[TBL] [Abstract][Full Text] [Related]
15. A Laboratory Session to Prepare Pharmacy Students to Manage the Opioid Crisis Situation.
Donohoe KL; Raghavan A; Tran TT; Alotaibi FM; Powers KE; Frankart LM
Am J Pharm Educ; 2019 Sep; 83(7):6988. PubMed ID: 31619820
[No Abstract] [Full Text] [Related]
16. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone.
Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K
J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a pharmacist-led naloxone coprescribing program in primary care.
Cariveau D; Fay AE; Baker D; Fagan EB; Wilson CG
J Am Pharm Assoc (2003); 2019; 59(6):867-871. PubMed ID: 31466899
[TBL] [Abstract][Full Text] [Related]
18. Implementation of a naloxone dispensing program in a grocery store-based community pharmacy.
Wilkerson DM; Groves BK; Mehta BH
Am J Health Syst Pharm; 2020 Mar; 77(7):511-514. PubMed ID: 32086505
[No Abstract] [Full Text] [Related]
19. Dispensing Naloxone Without a Prescription: Survey Evaluation of Ohio Pharmacists.
Thompson EL; Rao PSS; Hayes C; Purtill C
J Pharm Pract; 2019 Aug; 32(4):412-421. PubMed ID: 29478362
[TBL] [Abstract][Full Text] [Related]
20. Naloxone for Opioid Overdose and the Role of the Pharmacist.
Toderika Y; Williams S
Consult Pharm; 2018 Feb; 33(2):98-104. PubMed ID: 29409576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]